NCT04414631View on ClinicalTrials.gov

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 6, 2020

Primary Completion Date

September 15, 2021

Study Completion Date

September 15, 2021

Conditions
Coronavirus Infections
Interventions
DRUG

Conestat alfa

Conestat alfa (8400 Units (U) followed by 4200 U every 8 hours, 9 administrations in total) will be administered as a slow intravenous injection (5-10 minutes) over a 72 hour period.

Trial Locations (5)

4031

University Hospital Basel, Division of Internal Medicine, Basel

8063

Stadtspital Triemli, Departement Innere Medizin, Zurich

9007

Kantonsspital St. Gallen, Klinik für Infektiologie/Spitalhygiene, Sankt Gallen

09090-790

Práxis Pesquisa Medica, São Paulo

C.P 64460

"Hospital Universitario Dr. José Eleiterio González, Colinia Mitras Centro", Monterrey

Sponsors
All Listed Sponsors
collaborator

Pharming Technologies B.V.

INDUSTRY

lead

University Hospital, Basel, Switzerland

OTHER